Seragon Pharmaceuticals Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.73B
Latest Deal Amount

Seragon Pharmaceuticals General Information

Description

Developer of orally active selective estrogen receptor degraders (SERDs) that represent a treatment for metastatic breast cancer. The company is developing breast cancer pharmaceuticals based on the selective estrogen receptor degraders platform, including its lead drug candidate, ARN-810, under evaluation for ER+ breast cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 12780 El Camino Real
  • Suite 302
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Seragon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 27-Aug-2014 $1.73B 0000 00.000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 21-Aug-2013 0000 0000 Completed Product Development
1. Spin-Off 01-Jul-2013 Completed Product Development
To view Seragon Pharmaceuticals’s complete valuation and funding history, request access »

Seragon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of orally active selective estrogen receptor degraders (SERDs) that represent a treatment for metastatic breas
Drug Discovery
San Diego, CA
0000
0.000 0000-00-00
000000&0 0000

00000000

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
000000000000000
West Conshohocken, PA
00 As of 0000
000.00
000000 - 000 000.00

000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seragon Pharmaceuticals Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Madrigal Pharmaceuticals Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Tarrytown, NY 0000 00000 00000000000 00000
0000 00000000 Formerly VC-backed Stamford, CT 00 00000 000000&0 00000
You’re viewing 5 of 20 competitors. Get the full list »

Seragon Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
Patricia Millican Acting Chief Financial Officer
Nicholas Smith Ph.D Vice President, Chemistry
Charles Sawyers MD Advisor
You’re viewing 3 of 5 executive team members. Get the full list »

Seragon Pharmaceuticals Board Members (8)

Name Representing Role Since
Carol Gallagher MD Self Board Member 000 0000
You’re viewing 1 of 8 board members. Get the full list »

Seragon Pharmaceuticals Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Aragon Pharmaceuticals Corporation Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
The Column Group Venture Capital Minority 000 0000 000000 0
Topspin Venture Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »